Open AccessComparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
Author(s) -
Gibson C. Michael,
Korjian Serge,
Chi Gerald,
Daaboul Yazan,
Jain Purva,
Arbetter Douglas,
Goldhaber Samuel Z.,
Hull Russel,
Hernandez Adrian F.,
Lopes Renato D.,
Gold Alex,
Cohen Alexander T.,
Harrington Robert A.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.006015
Subject(s) - medicine , hazard ratio , absolute risk reduction , myocardial infarction , pulmonary embolism , number needed to harm , stroke (engine) , number needed to treat , relative risk , surgery , anesthesia , confidence interval , mechanical engineering , engineering
Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.